Skip to content

UFP Technologies

US · UFPT #2677 by market cap Listed 1970
292.87 -10.00 -3.30%
Live - 5344 symbols - heartbeat 110s ago · 2026-10-08 08:20
Pre-market 289.10 -1.29%
After-hours 292.87 0.00%
Market cap
2.27B
P/B
4.91
EPS
8.75
Reader sentiment Are you bullish or bearish on UFPT?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Near fair value
211.67 fair value ≈ 275.87 340.07
  • Implied fair-value range of 211.67-340.07, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +6.2% above the average-multiple fair value of 275.87.

Valuation each multiple against its own 5-year range

P/B ratio 5.07 Expensive vs history 71st percentile
5-year average 4.64 · #90 of 125 in Medical Devices
P/E ratio 32.74 In line with history 67th percentile
5-year average 31.53 · forward 30.01 · #25 of 38 in Medical Devices
P/S ratio 3.71 Expensive vs history 76th percentile
5-year average 3.36 · forward 3.49 · #85 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
UFP Technologies (UFPT) 2.27B 31.66 4.91 0.00%
Abbott Laboratories (ABT) 170.84B 31.95 3.34 2.47%
Medtronic (MDT) 109.38B 21.06 2.18 3.33%
Stryker Corp (SYK) 105.64B 28.54 4.40 1.26%
Boston Scientific (BSX) 60.26B 16.83 2.42 0.00%
Edwards Lifesciences (EW) 49.44B 49.87 4.66 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value279.93 Economic moatNarrow UncertaintyHigh

Trading 4.4% above Morningstar's fair value estimate.

Fair value

UFP Technologies Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 10% premium over our quantitative fair value estimate of $279.93 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's valuation metrics weaken our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 19.9%, which falls in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 26.9%, for example, ranks in the bottom 30% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-08 08:20:06 · For reference only, not investment advice and not tailored to your situation.